Item 7.01 Regulation FD Disclosure.



On March 30, 2021, VYNE Therapeutics Inc. (the "Company") updated its investor
presentation to include a slide summarizing the payor coverage with respect to
AMZEEQ® (minocycline) topical foam, 4%, and ZILXI® (minocycline) topical foam,
1.5%. The Company updated the investor presentation following the decision by
CVS Caremark ("Caremark") to not include these products, and other new branded
comparator drugs, on its national formulary for 2021. The slide also reflects
the decision by many Caremark custom plans to include the Company's products on
their respective formularies. A copy of the updated investor presentation,
including the new slide 20, is attached as Exhibit 99.1 to this current report
on Form 8-K.
The information in Item 7.01 of this Form 8-K and Exhibit 99.1 attached hereto
shall not be deemed "filed" for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to
the liabilities of that Section, or incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act, except as
shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
The following exhibit is being furnished herewith.
Exhibit No.           Description

99.1                    Investor Presentation, March 2021.

104                   Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses